Tag Chris Boshoff

Company News, News, Statements

Pfizer announced the successful completion of its acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

Pfizer today announced the successful completion of its acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share,…

December 14, 2023

New Treatments, News

Astellas Pharma and Pfizer announced that they received an approval by the FDA of a supplemental New Drug Application for XTANDI®.

Astellas Pharma and Pfizer today announced that the companies received an approval by the FDA of a supplemental New Drug Application for XTANDI® (enzalutamide), following FDA expedited development and review programs (Priority Review designation, Fast Track designation, Real-time Oncology Review),…

November 16, 2023

New Treatments, News

FDA approves BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic NSCLC. Pfizer announced that FDA has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as…

October 12, 2023